Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.35 |
| ▸ | PLK4 | O00444 | 2/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 4/20 | 0.33 |
| ▸ | AURKA | O14965 | 5/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298720 | 0.91 | DHODH (0.38) | DHODHNTRK1PLK4PAK4NTRK3 | |
| SCHEMBL1298437 | 0.88 | IGF1R (0.36) | DHODHNTRK1PLK4PAK4NTRK3 | |
| SCHEMBL1298967 | 0.87 | AURKA (0.36) | DHODHNTRK1PLK4PAK4NTRK3 | |
| SCHEMBL1298991 | 0.86 | DHODH (0.37) | DHODHNTRK1PLK4PAK4NTRK3 | |
| SCHEMBL1298354 | 0.86 | AURKA (0.39) | NTRK1RETAURKAAURKB | |
| SCHEMBL1299082 | 0.85 | DHODH (0.40) | DHODHNTRK1PLK4PAK4NTRK3 | |
| SCHEMBL1298579 | 0.85 | DHODH (0.40) | DHODHNTRK1PLK4PAK4NTRK3 | |
| SCHEMBL1298510 | 0.85 | DHODH (0.40) | DHODHNTRK1PLK4PAK4NTRK3 | |
| SCHEMBL1298355 | 0.85 | AURKA (0.37) | NTRK1RETAURKAAURKB | |
| SCHEMBL1298396 | 0.83 | AURKA (0.34) | DHODHNTRK1PLK4PAK4NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | claimed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | claimed |
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | DHODH 3113/4885NTRK1 1980/4885PLK4 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.